PARIS, FRANCE / ACCESS Newswire / December 16, 2025 / One year after deploying CaloPix®, the digital pathology platform developed…
PARIS, FRANCE / ACCESS Newswire / December 16, 2025 / One year after deploying CaloPix®, the digital pathology platform developed…
PARIS, FRANCE / ACCESS Newswire / December 16, 2025 / One year after deploying CaloPix®, the digital pathology platform developed…
Regulatory submission marks a significant milestone as the Company advances toward Phase 2/3 trial initiation in Q2 2026 at full…
Regulatory submission marks a significant milestone as the Company advances toward Phase 2/3 trial initiation in Q2 2026 at full…
Regulatory submission marks a significant milestone as the Company advances toward Phase 2/3 trial initiation in Q2 2026 at full…
TORONTO, Dec. 16, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0),…
TORONTO, Dec. 16, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0),…
TORONTO, Dec. 16, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0),…
TYLER, Texas--(BUSINESS WIRE)--ENvue Medical, Inc. (NASDAQ: FEED) (“ENvue” or the “Company”), a medical technology company specializing in non-invasive therapeutic systems,…